Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
Review of Family and Social Contact Restrictions for Patients Following Lu-177 Treatment (EANM 2026) - Sep 29, 2026 - Abstract #EPS-181; Pres time: Oct 20, 2026; 08:00 AM - 09:30 AM; Location: Hall G2; "An updated protocol with specific restriction tables for [Lu-177]PSMA-617 treatments has been successfully developed. Based on the 24-hour equivalent dose rate and accounting for the increased number of treatment cycles per patient, these new guidelines ensure a safe hospital discharge and guarantee the radiation protection of family members and caregivers in accordance with international standards." 
Clinical • Review
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
M. Serrano Campillo; O. Rosas Lozano; C. González Navarro; M. Catalá Espí; Á. García Aliaga; F. García Cases
 
Sep 29, 2026
 
Prev Next